erlotinib hydrochloride has been researched along with silybin in 3 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (silybin) | Trials (silybin) | Recent Studies (post-2010) (silybin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,133 | 31 | 816 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheon, GJ; Choi, CM; Choi, SJ; Choi, YJ; Jeon, BS; Kim, CH; Kim, HR; Lee, JC; Rho, JK; Woo, SK | 1 |
| Barrajón-Catalán, E; Bonavia, R; Bosch-Barrera, J; Corominas-Faja, B; Cufí, S; Cuyàs, E; Joven, J; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Segura-Carretero, A; Vazquez-Martin, A; Visa, J | 1 |
| Barrajón-Catalán, E; Bosch-Barrera, J; Corominas-Faja, B; Cuyàs, E; Joven, J; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Segura-Carretero, A | 1 |
3 other study(ies) available for erlotinib hydrochloride and silybin
| Article | Year |
|---|---|
Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.
Topics: Amino Acid Substitution; Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mutation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Signal Transduction; Silybin; Silymarin; Tyrosine; Xenograft Model Antitumor Assays | 2010 |
Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Mice; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Silybin; Silymarin; Treatment Outcome | 2013 |
Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
Topics: Aldehyde Oxidoreductases; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Genotype; Humans; Lung Neoplasms; Mutation; Neoplastic Stem Cells; Phenotype; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Silybin; Silymarin; Spheroids, Cellular; Tumor Cells, Cultured | 2013 |